Mylan Stock Buy Or Sell Now

Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ).

Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook mylan stock buy or sell

~$14.67, indicating a slight forecasted downside of roughly -1% . Target Range: High of $18.00 and a low of $10.00 . Investment Case: Buy vs. Sell Buy Case (Bullish) Sell/Hold Case (Bearish) Mylan (formerly NASDAQ: MYL) no longer exists as

Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 . Financial Health & Outlook ~$14

The consensus among Wall Street analysts is currently a . While some analysts maintain a "Buy" rating, recent price targets suggest limited immediate upside. Current Stock Price: ~$14.81 (as of April 27, 2026).

Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds.

To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026)